23 / 39
conferenceseries
.com
Page 54
Notes:
Volume 7, Issue 6 (Suppl)
J Biotechnol Biomater, an open access journal
ISSN: 2155-952X
World Biotechnology 2017
December 04-05, 2017
2
nd
World Biotechnology Congress
December 04-05, 2017 | Sao Paulo, Brazil
The future of pharmaceutical biotechnology with the Industry 4.0: Managing new technologies, teams and
reaching customers from baby boomers to the i-generation
Wilker Ribeiro Filho
Instituto Reger, Brazil
T
he use of tools like Artificial Intelligence (AI), robotics, mobile devices, cloud computing, big data analysis, internet of things and
others, are already changing the way we do basic research, products development, innovation, promote sales, perform medical
diagnostics, advice treatments and purchase medicines. The world is changing faster day after day. The increase of life expectancy is
creating a bigger mix of generations in the work force and consumer habits. Professionals of today, may drastically be reduced or even
no longer exist in less than 20 years including scientists, medical doctors, sales personnel, lawyers, being substituted by new hardware
and software technologies or new types of professionals. Pharmaceutical and other areas of biotechnology in all of its’ production
chains, from basic research to reaching their customers, will and is already being highly affected. On the way to reaching customers
and making profits, is the challenge of managing teams from different generations, with a different way of doing things, and making
them be challenged, interested, productive. The Industry 4.0 should not be seen only with on the technology point of view, but with
the whole system involved that will be definitive to the survival of companies, no matter how big they are today. A start up may be
able to knock down a super pharma becoming a big hit in just 10 years with innovative technologies and products. Being open and
prepared in advance for these changes is key to survive the future not so yet to come. The use of the new technologies becoming more
available daily, shall increase results for new products and treatments, as much as reduce general costs from research to production,
distribution, marketing and sales. Management shall be the key. Manage the use and the application of technologies and they profile
of personnel. Each generation has a different way of seeing things, learning, doing, purchasing and the companies must be prepared
from now. Prepare for adaption from now, or perish.
Biography
Wilker Ribeiro Filho is a Biologist, PhD in Medical Science, specialist in pharmaceutical technology and MBA in Business Management. He has experience in public policies
for industrial development of the biotech industry, project’s management, businesses evaluation and management, innovation, building and managing triple helix teams
with technical and C level participants. With the experience from lab tests to higher level management, he has interest in relearning things from bottom and up. Innovative,
brings and forms new views and ideas when gathering old information with new ones, some yet to come, to improve competitiveness and results for partners, companies
and other stake holders.
wilkersnake@hotmail.comWilker Ribeiro Filho, J Biotechnol Biomater 2017, 7:6 (Suppl)
DOI: 10.4172/2155-952X-C1-085